India's Sun brings home Taro CEO as business plan accelerates

Indian flag

Mumbai-based Sun Pharmaceutical Industries has decided to bring the CEO of its Taro unit--Kal Sundaram--back from the U.S. to the head office in India by the end of the year as plans to consolidate manufacturing and other operations ramp up. 

Sundaram headed Taro following an acrimonious takeover effort by Sun's MD and founder, Dilip Shanghvi, from the Israel-based founders that ended in 2010.

He helped steer the previously unprofitable company to sales of $950 million in the year ending March of this year, with net profit hitting $450 million, according to the Economic Times.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

In earnings for the year ended March 31, released in May, Sun--the world's fifth largest generics maker--said it was confident a massive reorganization to consolidate operations after its purchase of Ranbaxy Laboratories in 2014 were "on track," and in particular lauded progress in the U.S. market.

A replacement for Sundaram at Taro and the exact title of his new role at headquarters were not announced.

- here's the release
- and a story from the Economic Times

Related Articles:
India's Sun says consolidation efforts on track, eyes share buyback

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…